PowderJect to start vaccine trial

PowderJect is to start clinical trials of a vaccine to combat hepatitis B as part of its continuing strategic alliance with GlaxoSmithKline.

PowderJect is to start clinical trials of a vaccine to combat hepatitis B as part of its continuing strategic alliance with GlaxoSmithKline.

Oxford-based PowderJect, through its subsidiary PowderJect Vaccines, will study the effectiveness of a DNA immunotherapeutic treatment to combat hepatitis B, the chronic viral infection.

You have reached your article limit. Already a subscriber? Sign in

Clubber TV and Irish Examiner logos in offer banner

Every Match. Every Story.

One Ultimate Bundle

No obligation. Ts&Cs apply.

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited